BlackRock Health Sciences Trust

BlackRock Health Sciences Trust carries $894K in total debt against $548 in cash reserves — debt is roughly 1632.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$2.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 13.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from -$26.0M (2022) to $77.5M (2025), reflecting a 399% increase over the period.

With a beta below 0.7, BlackRock Health Sciences Trust typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BlackRock Health Sciences Trust and its sector.